ciprofloxacin has been researched along with Infections, Respiratory in 222 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 10.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs)." | 9.30 | Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ( Bo, SN; Gai, XY; Lu, W; Shen, N; Yin, AY; Zhou, QT, 2019) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 9.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| " Ambulatory adults with lower respiratory tract infections were randomly assigned to receive temafloxacin 600 mg or ciprofloxacin 750 mg, each given every 12 h for 7-14 days." | 9.07 | Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomized, double-blind trial. ( Carnegie, CM; Lindsay, G; Scorer, HJ, 1992) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 9.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "The purpose of this study was to determine the effects of smoking history and age on the efficacy and safety of temafloxacin versus ciprofloxacin or amoxicillin in patients with lower respiratory tract infections (LRTIs)." | 9.07 | Efficacy of temafloxacin versus ciprofloxacin or amoxicillin for lower respiratory tract infections in smokers and the elderly. ( Davey, PG, 1991) |
| "The efficacy and safety of sequential intravenous/oral ciprofloxacin in moderate to severe respiratory tract infections (RTI) were compared with those of ceftazidime in a prospective clinical trial." | 9.06 | Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. ( Basir, R; Khan, FA, 1989) |
| "This study determined the efficacy of intravenous ciprofloxacin in the treatment of institutionalized patients with lower respiratory tract infections." | 9.06 | Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. ( Gvazdinskas, LC; Levin, S; Schmitt, BA; Spear, J; Trenholme, GM, 1989) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 9.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| "Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks." | 9.06 | Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ( Chartrand, SA; Greenwood, R; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Twenty patients with lower respiratory tract infections presumably caused by ciprofloxacin-susceptible bacteria were admitted to a non-comparative, prospective clinical study." | 9.06 | Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis. ( Bianchi, W; Esposito, S; Gagliardi, R; Galante, D, 1987) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 9.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 8.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "Moxifloxacin has potent bactericidal activity against Streptococcus pneumoniae; a major causative organism of lower respiratory tract infections." | 7.80 | Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. ( Noreddin, AM; Salem, AH, 2014) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 7.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 7.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 6.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 6.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 6.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "Ciprofloxacin was as effective as ampicillin and produced a 98 percent clinical cure rate." | 6.66 | Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. ( Afzal, Q; Guarneri, JJ; Khan, FA; LaBombardi, V; Raoof, S; Wollschlager, CM, 1987) |
| "The clinical efficacy, safety, and optimal dosage of oral ciprofloxacin for the treatment of respiratory infections were studied in a multicenter, open trial in Japan." | 6.66 | Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. ( Kobayashi, H, 1987) |
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 6.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs)." | 5.30 | Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. ( Bo, SN; Gai, XY; Lu, W; Shen, N; Yin, AY; Zhou, QT, 2019) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 5.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| " Adverse events were recorded in only two patients and involved a slight elevation in liver function tests and eosinophilia." | 5.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| " The higher dosage showed a reduced amount of reinfections and relapses (19% and 16% versus 5% and 0%)." | 5.28 | Two different dosages of ciprofloxacin in patients with respiratory tract infections. ( Brutel de la Rivière, T; Daniëls-Bosman, MS; ten Velde, GP, 1989) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 5.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| " Ambulatory adults with lower respiratory tract infections were randomly assigned to receive temafloxacin 600 mg or ciprofloxacin 750 mg, each given every 12 h for 7-14 days." | 5.07 | Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomized, double-blind trial. ( Carnegie, CM; Lindsay, G; Scorer, HJ, 1992) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 5.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "The purpose of this study was to determine the effects of smoking history and age on the efficacy and safety of temafloxacin versus ciprofloxacin or amoxicillin in patients with lower respiratory tract infections (LRTIs)." | 5.07 | Efficacy of temafloxacin versus ciprofloxacin or amoxicillin for lower respiratory tract infections in smokers and the elderly. ( Davey, PG, 1991) |
| "The efficacy and safety of sequential intravenous/oral ciprofloxacin in moderate to severe respiratory tract infections (RTI) were compared with those of ceftazidime in a prospective clinical trial." | 5.06 | Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. ( Basir, R; Khan, FA, 1989) |
| "This study determined the efficacy of intravenous ciprofloxacin in the treatment of institutionalized patients with lower respiratory tract infections." | 5.06 | Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. ( Gvazdinskas, LC; Levin, S; Schmitt, BA; Spear, J; Trenholme, GM, 1989) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 5.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| "Thirty one patients were treated with oral ciprofloxacin for bronchitis with Pseudomonas aeruginosa." | 5.06 | Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa. ( Haverkorn, MJ, 1987) |
| "Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks." | 5.06 | Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. ( Chartrand, SA; Greenwood, R; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Twenty patients with lower respiratory tract infections presumably caused by ciprofloxacin-susceptible bacteria were admitted to a non-comparative, prospective clinical study." | 5.06 | Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis. ( Bianchi, W; Esposito, S; Gagliardi, R; Galante, D, 1987) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 5.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 4.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "urinary tract infections." | 3.85 | In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. ( Linasmita, P; Tantisiriwat, W, 2017) |
| "Moxifloxacin has potent bactericidal activity against Streptococcus pneumoniae; a major causative organism of lower respiratory tract infections." | 3.80 | Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. ( Noreddin, AM; Salem, AH, 2014) |
| "The aim of this study was to compare the pharmacokinetics and efficacy of ciprofloxacin as post-exposure therapy against inhalational anthrax in the common marmoset (Callithrix jacchus) with other non-human primate models in order to determine whether the marmoset is a suitable model to test post-exposure therapies for anthrax." | 3.77 | Post-exposure therapy of inhalational anthrax in the common marmoset. ( Brown, MA; Lever, MS; Nelson, M; Pearce, PC; Simpson, AJ; Stagg, AJ; Stevens, DJ, 2011) |
| "Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections." | 3.76 | A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06). ( Finley, R; Glass, SK; McEwen, SA; Pearl, DL, 2010) |
| "The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections." | 3.71 | Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. ( Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V, 2001) |
| "Ciprofloxacin or doxycycline is recommended for antimicrobial prophylaxis and treatment of adults and children with Bacillus anthracis infection associated with the recent bioterrorist attacks in the United States." | 3.71 | Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. ( , 2001) |
| "Ciprofloxacin, a quinolone antibiotic, is used to treat a wide variety of infections including Pseudomonas aeruginosa in patients with cystic fibrosis (CF)." | 3.70 | If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin. ( Bush, A; Jaffé, A, 1999) |
| "Ciprofloxacin is a fluoroquinolone antibiotic effective in the treatment of lower respiratory tract infections (LRTI)." | 3.70 | Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. ( Baraldo, M; Furlanut, M; Lugatti, E; Milaneschi, R; Pea, F; Talmassons, G, 2000) |
| "Ciprofloxacin may be considered as first-line treatment for a number of infections in which gram-negative pathogens are proven or strongly suspected, including complicated urinary tract infections, bacterial prostatitis, bacterial diarrhea, selected bone and joint infections, malignant otitis externa, bronchopulmonary infections in patients with cystic fibrosis and selected pneumonia cases." | 3.69 | Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society. ( Louie, TJ, 1994) |
| "We report the case of a female patient who presented fixed exanthema following administration of ciprofloxacin." | 3.69 | Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin. ( Fernández de Miguel, C; Gómez Martinez, M; Laguna Martinez, JJ; Lozano Ayllón, M; Mosquera, MR; Orta Martiartu, M, 1995) |
| "Preincubation with subinhibitory concentrations of sparfloxacin, ciprofloxacin, and trimethoprim decreased the adherence of the respiratory pathogens Klebsiella pneumoniae, Haemophilus influenzae, and Moraxella (Branhamella) catarrhalis to human larynx carcinoma HEp-2 cells." | 3.68 | Changes in adherence of respiratory pathogens to HEp-2 cells induced by subinhibitory concentrations of sparfloxacin, ciprofloxacin, and trimethoprim. ( Beumer, H; Hoepelman, AI; Rozenberg-Arska, M; Verhoef, J; Visser, MR, 1993) |
| "Intravenous ciprofloxacin is approved for the treatment of urinary tract, bone and joint, skin and soft tissue, and lower respiratory tract infections." | 3.68 | Intravenous ciprofloxacin: a position statement by the Society of Infectious Diseases Pharmacists. ( , 1993) |
| "The authors evaluate the clinical efficacy and tolerability of the new wide-spectrum fluoroquinolone ciprofloxacin for management of respiratory tract infections." | 3.68 | [Ciprofloxacin in the treatment of respiratory infections]. ( Doddi, M; Lauri, A; Placidi, C; Poggi, F; Tognazzi, F, 1990) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 3.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "The steady-state pharmacokinetics of ciprofloxacin were evaluated in nine elderly patients with lower respiratory tract infections after an intravenous dosage regimen of 200 mg every 12 h (n = 9) and an oral dosage regimen of 750 mg every 12 h (n = 6)." | 3.67 | Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients. ( Awni, WM; Guay, DR; Hirata, CA; Peterson, PK; Stein, DJ, 1989) |
| "Oral quinolones such as ciprofloxacin are promising agents in the treatment of serious bronchopulmonary infections due to susceptible gram-negative micro-organisms such as Haemophilus influenzae, Branhamella catarrhalis, Klebsiella pneumoniae and even Pseudomonas aeruginosa." | 3.67 | Role of fluoroquinolones in lower respiratory tract infections. ( Vellend, H, 1989) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 3.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 2.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| "Upper respiratory tract infections (URTI) frequently cause exacerbations of chronic-obstructive pulmonary disease (COPD)." | 2.76 | Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial. ( Isbaniah, F; Setiawati, A; Totzke, U; Verbruggen, MA; Wiyono, WH; Yunus, F, 2011) |
| "Lomefloxacin was suggested to be the most advantageous drug in the treatment of elderly patients with LRTI because of its easy use, practically no dependence of the pharmacokinetics on the patient age and almost no nephrotoxic action." | 2.69 | [Selection of antibacterial therapy for treatment of infections in elderly patients]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP, 1998) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 2.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| " The once daily dosage of fleroxacin [400 mg once daily intravenously (i." | 2.68 | Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. ( Marklein, G, 1996) |
| "The lower respiratory tract infections caused by E." | 2.68 | [The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association]. ( , 1997) |
| "Ciprofloxacin was administered to 113 cases and roxythromycin to 220 cases by doctors in charge." | 2.67 | [Studies on respiratory infections in primary care clinic (V). The pattern of distribution on bacteria, Mycoplasma pneumoniae and virus isolated from patients with respiratory infections, who were seen in six private clinics, and clinical efficacy of cipr ( Aonuma, S; Hoshi, Y; Nagashima, M; Nishino, T; Nukiwa, T; Sato, S; Shoji, M; Shoji, S; Tsunoda, A; Watanabe, A, 1994) |
| " The patients were treated with Bay-o-9867 (ciprofloxacin) administered orally at a daily dosage of 500 mg (250 q 12 h) in 30 patients and of 1000 mg (500 q 12 h) in 10 patients, depending on the severity of infection." | 2.67 | [The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract]. ( Bolognesi, S; Quartieri, F; Sconosciuto, F, 1994) |
| "Also for lower respiratory tract infections (LTRI) the clinical and bacteriological responses were quite similar, although relatively more failures occurred in CF treated patients with LRTI caused by pneumococci." | 2.67 | Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. ( Andersen, BM; Bergan, T; Brubakk, O; Bruun, JN; Døskeland, B; Hellum, KB; Hopen, G; Kalager, T; Rahm, V; von der Lippe, E, 1992) |
| "Ciprofloxacin was given as an initial 100 mg twice daily as intravenous infusion, and this was switched to an oral form of 500 mg b." | 2.67 | Ciprofloxacin in severe infections. ( Aswapokee, N; Aswapokee, P; Pruksachatvuthi, S, 1990) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 2.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "Ciprofloxacin was as effective as ampicillin and produced a 98 percent clinical cure rate." | 2.66 | Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. ( Afzal, Q; Guarneri, JJ; Khan, FA; LaBombardi, V; Raoof, S; Wollschlager, CM, 1987) |
| "The clinical efficacy, safety, and optimal dosage of oral ciprofloxacin for the treatment of respiratory infections were studied in a multicenter, open trial in Japan." | 2.66 | Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. ( Kobayashi, H, 1987) |
| "Fifty-two patients with serious respiratory infections were treated with orally administered ciprofloxacin; 42 patients were evaluable for the efficacy analysis and all were evaluable for determining adverse reactions." | 2.66 | Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. ( Fass, RJ, 1987) |
| " In general, the patients received ciprofloxacin at a dosage of 250 to 750 mg every 12 hours; the median dose was 500 mg twice daily." | 2.66 | Ciprofloxacin: an update on clinical experience. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B, 1987) |
| "Ciprofloxacin was as effective as amoxycillin with a successful outcome in 81% and 82% of cases respectively." | 2.66 | Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. ( Ferguson, WP; Gleadhill, IC; Lowry, RC, 1986) |
| "Initially, DDS for the treatment of atherosclerosis are described." | 2.44 | [Development of drug delivery systems for targeting to macrophages]. ( Chono, S, 2007) |
| "Ciprofloxacin is an effective treatment for those infections most common in elderly patients, including infections of the urinary tract, lower respiratory tract, skin and soft-tissues, and bone and joints, and is an effective agent for prophylaxis in transurethral surgery." | 2.39 | Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. ( Balfour, JA; Wiseman, LR, 1994) |
| "Ciprofloxacin is a fluorinate quinolone with a broad spectrum of activity against gram-positive and gram-negative organisms." | 2.38 | [A review of clinical studies on the efficacy and tolerance of intravenous ciprofloxacin]. ( Memoli, M, 1992) |
| "Ciprofloxacin is a new 4-quinolone antibacterial agent with an extended antibacterial spectrum, enhanced potency and the ability to produce therapeutic serum, tissue and urine concentrations after oral administration." | 2.37 | Overview of clinical experience with ciprofloxacin. ( Ball, AP, 1986) |
| "Upper respiratory infections were characterized by acute infection of nasal cavity, pharynx and larynx while lower respiratory infections were characterized by chest pains, prolonged cough, productive sputum, difficulty in breathing, fever and weight loss." | 1.91 | Study of bacterial respiratory infections and antimicrobial susceptibility profile among antibiotics naive outpatients visiting Meru teaching and referral hospital, Meru County, Kenya in 2018. ( Miriti, DM; Muthini, JM; Nyamache, AK, 2023) |
| " Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens." | 1.56 | Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines. ( Barnewall, RE; Ionin, B; Lemiale, L; Park, S; Perry, MR; Reece, JJ; Savransky, V; Shearer, JD; Skiadopoulos, MH; Vassar, ML, 2020) |
| " Previously, we demonstrated that the complexation of CIP with copper (CIP-Cu) reduces its apparent epithelial permeability and pulmonary absorption rate without affecting antimicrobial activity against Pseudomonas aeruginosa grown planktonically or as biofilms." | 1.56 | In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa. ( Bahamondez-Canas, TF; Moraga-Espinoza, D; Smyth, HDC; Tewes, F; Watts, AB, 2020) |
| "Anthrax is a zoonotic occupational disease caused by Bacillus anthracis, a rod-shaped immobile aerobic gram-positive bacteria with spore." | 1.43 | A case report of inhalation anthrax acquired naturally. ( Azarkar, Z; Bidaki, MZ, 2016) |
| "Clarithromycin and rifampin were shown to be effective only as a postexposure prophylactic treatment but failed to treat the systemic (bacteremic) phase of anthrax." | 1.42 | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. ( Altboum, Z; Bar-David, E; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2015) |
| "To analyse population pharmacokinetic (PPK) parameter values of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection." | 1.42 | [Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection]. ( Bo, S; Gai, X; He, B; Li, X; Lu, W; Shen, N; Yin, A; Zhai, S; Zhou, Q, 2015) |
| " The Orbital(®) dry powder device is designed to deliver high doses of drugs to the respiratory tract in a single dosing unit, via multiple inhalation maneuvers, overcoming the need to prime or insert multiple capsules." | 1.40 | Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. ( Chan, HK; Crapper, J; Philips, G; Sharma, K; Traini, D; Young, PM, 2014) |
| "Ciprofloxacin was prescribed for 37 (2." | 1.37 | Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. ( Blasi, F; Butler, CC; Coenen, S; Goossens, H; Hood, K; Kelly, MJ; Little, P; Nuttall, J; Schaberg, T; Torres, A; Verheij, T; Wood, J, 2011) |
| "Ciprofloxacin was used in a large proportion of the patients in cases when another antibiotic should have been the first choice according to Norwegian national guidelines." | 1.36 | [Use of fluoroquinolones in nursing homes]. ( Fagan, M; Skotheim, SB, 2010) |
| "Fifty-three Mycoplasma pneumoniae strains were isolated from pediatric patients in Shanghai, China, from October 2005 to February 2008." | 1.35 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. ( Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D, 2009) |
| "Ciprofloxacin-resistance was found in 4% of isolates." | 1.35 | Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. ( Hansen, CR; Høiby, N; Pressler, T, 2008) |
| "aeruginosa respiratory tract infections and to develop a tool to estimate the probability of MDR among such high-risk patients." | 1.34 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. ( Furuno, JP; Graffunder, E; Graves, J; Lodise, TP; Lomaestro, B; McGregor, JC; McNutt, LA; Miller, CD, 2007) |
| "The pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin (CPFX) for the treatment of respiratory infections caused by pathogenic microorganisms resisting sterilization systems of alveolar macrophages (AMs) was evaluated by comparison with an oral administration." | 1.34 | Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. ( Chono, S; Morimoto, K; Seki, T; Tanino, T, 2007) |
| "Clarithromycin resistance was 12% in M." | 1.33 | Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia. ( Altraja, A; Kullamaa, A; Leesik, H; Meriste, S; Naaber, P; Tamm, E, 2006) |
| "The incidence of nosocomial infections in patients after ICAAS fell from 78." | 1.32 | Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials. ( Beovic, B; Bosnjak, R; Cizman, M; Hergouth-Krizan, V; Matos, B; Mueller-Premru, M; Seme, K, 2003) |
| " Plasma concentration curves were simulated from literature values of the pharmacokinetic parameters of the drug and the age and weight of the patients." | 1.31 | Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. ( Coloma Milano, C; Sánchez Navarro, MD; Sánchez-Navarro, A; Sayalero Marinero, ML; Zarzuelo Castañeda, A, 2002) |
| " This report updates the investigation of these cases and describes adverse events associated with antimicrobial prophylaxis." | 1.31 | Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. ( , 2001) |
| " During October 26-November 6, 2001, an epidemiologic evaluation to detect adverse events associated with antimicrobial prophylaxis was conducted among 8,424 postal employees who had been offered antimicrobial prophylaxis for 60 days in New Jersey (NJ), New York City (NYC), and one postal facility in the District of Columbia (DC)." | 1.31 | Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001. ( , 2001) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 1.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| "catarrhalis produced beta-lactamase." | 1.30 | Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. ( Felmingham, D; Grüneberg, RN; Harding, I; Robbins, MJ; Shrimpton, S; Tesfaslasie, Y, 1998) |
| " Adverse events were recorded in only two patients and involved a slight elevation in liver function tests and eosinophilia." | 1.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| "Sparfloxacin was fourfold more active against Staphylococcus aureus and Streptococcus pneumoniae." | 1.29 | In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. ( Ahlén, S; Malmborg, AS, 1993) |
| "Against respiratory tract infections with K." | 1.28 | In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ( Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y, 1991) |
| "Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae." | 1.28 | Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. ( Beale, AS; Gisby, J; Wightman, BJ, 1991) |
| "Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria." | 1.28 | Intravenous ciprofloxacin for the treatment of severe infections. ( Baiocchi, P; Brandimarte, C; Gelfusa, V; Santini, C; Serra, P; Tarasi, A; Venditti, M, 1991) |
| "Ciprofloxacin was given twice a day, as 500 mg through a gastric tube or 200 mg intravenously, and both applications led to negative cultures for aerobic Gram-negative bacilli from faeces and throat, except for a few periods of carriage lasting only a few days." | 1.28 | Prophylaxis of respiratory tract infection in patients on artificial respiration. ( Haverkorn, MJ, 1989) |
| "Ciprofloxacin is a new fluorinated 4-quinolone with a broad spectrum of antimicrobial activity which includes both Gram-negative and Gram-positive bacteria." | 1.28 | Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens. ( Baskerville, AJ; Felmingham, D; Grüneberg, RN; Ridgway, GL; Robbins, MJ; Sanghrajka, MD, 1989) |
| " The higher dosage showed a reduced amount of reinfections and relapses (19% and 16% versus 5% and 0%)." | 1.28 | Two different dosages of ciprofloxacin in patients with respiratory tract infections. ( Brutel de la Rivière, T; Daniëls-Bosman, MS; ten Velde, GP, 1989) |
| "Ciprofloxacin was found to be the most active drug tested against all gram-negative organisms and streptococci, with the exception of Streptococcus faecalis and Streptococcus pneumoniae." | 1.27 | Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy. ( Hoogkamp-Korstanje, JA, 1984) |
| "Ciprofloxacin is an effective and safe therapeutic alternative in many tissue infections caused by susceptible microorganisms." | 1.27 | Open, prospective study of the clinical efficacy of ciprofloxacin. ( Bran, JL; Garcia, JF; Mejia, CR; Ramirez, CA, 1985) |
| "Ciprofloxacin is a new quinolone antimicrobial agent with activity against a broad spectrum of gram-negative and gram-positive organisms, including Pseudomonas aeruginosa and methicillin-resistant strains of staphylococci." | 1.27 | A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B; Screen, P, 1988) |
| " Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6." | 1.27 | Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ( Awni, WM; Breitenbucher, R; Guay, DR; Matzke, GR; Obaid, S; Peterson, PK; Stein, D, 1988) |
| " Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f), and apparent volume of distribution (Vd/f) of ciprofloxacin were 5." | 1.27 | Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. ( Awni, WM; Breitenbucher, R; Guay, DR; Matzke, GR; Obaid, S; Peterson, PK, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (23.87) | 18.7374 |
| 1990's | 69 (31.08) | 18.2507 |
| 2000's | 48 (21.62) | 29.6817 |
| 2010's | 44 (19.82) | 24.3611 |
| 2020's | 8 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| East, SP | 1 |
| Beckett, RP | 1 |
| Brookings, DC | 1 |
| Clements, JM | 1 |
| Doel, S | 1 |
| Keavey, K | 1 |
| Pain, G | 1 |
| Smith, HK | 1 |
| Thomas, W | 1 |
| Thompson, AJ | 1 |
| Todd, RS | 1 |
| Whittaker, M | 1 |
| Lodise, TP | 1 |
| Miller, CD | 1 |
| Graves, J | 1 |
| Furuno, JP | 1 |
| McGregor, JC | 1 |
| Lomaestro, B | 1 |
| Graffunder, E | 1 |
| McNutt, LA | 1 |
| Liu, Y | 1 |
| Ye, X | 1 |
| Zhang, H | 1 |
| Xu, X | 1 |
| Li, W | 1 |
| Zhu, D | 1 |
| Wang, M | 1 |
| Pérez-Trallero, E | 2 |
| Martín-Herrero, JE | 1 |
| Mazón, A | 1 |
| García-Delafuente, C | 1 |
| Robles, P | 1 |
| Iriarte, V | 1 |
| Dal-Ré, R | 1 |
| García-de-Lomas, J | 3 |
| Odagiri, T | 2 |
| Inagaki, H | 2 |
| Sugimoto, Y | 1 |
| Nagamochi, M | 2 |
| Miyauchi, RN | 1 |
| Kuroyanagi, J | 1 |
| Kitamura, T | 2 |
| Komoriya, S | 2 |
| Takahashi, H | 2 |
| Panchaud, P | 1 |
| Bruyère, T | 1 |
| Blumstein, AC | 1 |
| Bur, D | 1 |
| Chambovey, A | 1 |
| Ertel, EA | 1 |
| Gude, M | 1 |
| Hubschwerlen, C | 1 |
| Jacob, L | 1 |
| Kimmerlin, T | 1 |
| Pfeifer, T | 1 |
| Prade, L | 1 |
| Seiler, P | 1 |
| Ritz, D | 1 |
| Rueedi, G | 1 |
| Sarciaux, M | 1 |
| Pantel, L | 1 |
| Midrier, C | 1 |
| Serri, M | 1 |
| Gerber, C | 1 |
| Marcia de Figueiredo, R | 1 |
| Campagne, JM | 1 |
| Villain-Guillot, P | 1 |
| Gualtieri, M | 1 |
| Racine, E | 1 |
| Bhawsar, S | 1 |
| Joshi, S | 1 |
| Deshpande, P | 1 |
| Yeole, R | 1 |
| Bhagwat, S | 1 |
| Patel, M | 1 |
| Miriti, DM | 1 |
| Muthini, JM | 1 |
| Nyamache, AK | 1 |
| Chen, F | 1 |
| Fang, L | 1 |
| Feng, K | 1 |
| Xu, J | 1 |
| Lin, Y | 2 |
| Chang, RYK | 1 |
| Britton, WJ | 2 |
| Morales, S | 2 |
| Kutter, E | 2 |
| Li, J | 3 |
| Chan, HK | 3 |
| Torres, BGS | 1 |
| Awad, R | 1 |
| Marchand, S | 1 |
| Couet, W | 1 |
| Tewes, F | 2 |
| Yu, S | 1 |
| Wang, S | 1 |
| Zou, P | 1 |
| Chai, G | 1 |
| Lin, YW | 1 |
| Velkov, T | 1 |
| Pan, W | 1 |
| Zhou, QT | 2 |
| Perry, MR | 1 |
| Ionin, B | 1 |
| Barnewall, RE | 1 |
| Vassar, ML | 1 |
| Reece, JJ | 1 |
| Park, S | 1 |
| Lemiale, L | 1 |
| Skiadopoulos, MH | 1 |
| Shearer, JD | 1 |
| Savransky, V | 1 |
| Bahamondez-Canas, TF | 1 |
| Moraga-Espinoza, D | 1 |
| Smyth, HDC | 1 |
| Watts, AB | 1 |
| Vietri, NJ | 1 |
| Tobery, SA | 1 |
| Chabot, DJ | 1 |
| Ingavale, S | 1 |
| Somerville, BC | 1 |
| Miller, JA | 1 |
| Schellhase, CW | 1 |
| Twenhafel, NA | 1 |
| Fetterer, DP | 1 |
| Cote, CK | 1 |
| Klimko, CP | 1 |
| Boyer, AE | 1 |
| Woolfitt, AR | 1 |
| Barr, JR | 1 |
| Wright, ME | 1 |
| Friedlander, AM | 1 |
| Yoon Kyung Chang, R | 1 |
| Günday Türeli, N | 1 |
| Torge, A | 1 |
| Juntke, J | 1 |
| Schwarz, BC | 1 |
| Schneider-Daum, N | 1 |
| Türeli, AE | 1 |
| Lehr, CM | 1 |
| Schneider, M | 1 |
| Loo, CY | 1 |
| Lee, WH | 1 |
| Lauretani, G | 1 |
| Scalia, S | 1 |
| Cipolla, D | 1 |
| Traini, D | 2 |
| Young, P | 1 |
| Ong, HX | 1 |
| Tantisiriwat, W | 2 |
| Linasmita, P | 1 |
| Grădinaru, AC | 1 |
| Trifan, A | 1 |
| Şpac, A | 1 |
| Brebu, M | 1 |
| Miron, A | 1 |
| Aprotosoaie, AC | 1 |
| Haworth, CS | 1 |
| Bilton, D | 1 |
| Chalmers, JD | 1 |
| Davis, AM | 1 |
| Froehlich, J | 1 |
| Gonda, I | 1 |
| Thompson, B | 1 |
| Wanner, A | 1 |
| O'Donnell, AE | 1 |
| Gai, XY | 1 |
| Bo, SN | 1 |
| Shen, N | 2 |
| Yin, AY | 1 |
| Lu, W | 2 |
| Abdalla, A | 1 |
| Ramly, S | 1 |
| Boers, P | 1 |
| Casserly, L | 1 |
| Lu, Q | 1 |
| Yu, J | 1 |
| Bao, L | 1 |
| Ran, T | 1 |
| Zhong, H | 1 |
| Young, PM | 1 |
| Crapper, J | 1 |
| Philips, G | 1 |
| Sharma, K | 1 |
| Salem, AH | 1 |
| Noreddin, AM | 1 |
| Virok, DP | 1 |
| Ábrók, M | 1 |
| Szél, B | 1 |
| Tajti, Z | 1 |
| Mader, K | 1 |
| Urbán, E | 1 |
| Tálosi, G | 1 |
| Stass, H | 1 |
| Delesen, H | 1 |
| Nagelschmitz, J | 1 |
| Staab, D | 1 |
| Puig, C | 1 |
| Tirado-Vélez, JM | 1 |
| Calatayud, L | 1 |
| Tubau, F | 1 |
| Garmendia, J | 1 |
| Ardanuy, C | 1 |
| Marti, S | 1 |
| de la Campa, AG | 1 |
| Liñares, J | 1 |
| Connett, GJ | 1 |
| Pike, KC | 1 |
| Legg, JP | 1 |
| Cathie, K | 1 |
| Dewar, A | 1 |
| Foote, K | 1 |
| Harris, A | 1 |
| Faust, SN | 1 |
| Weiss, S | 1 |
| Altboum, Z | 1 |
| Glinert, I | 1 |
| Schlomovitz, J | 1 |
| Sittner, A | 1 |
| Bar-David, E | 1 |
| Kobiler, D | 1 |
| Levy, H | 1 |
| Gai, X | 1 |
| He, B | 1 |
| Zhou, Q | 1 |
| Bo, S | 1 |
| Li, X | 1 |
| Zhai, S | 1 |
| Yin, A | 1 |
| Langan, KM | 1 |
| Kotsimbos, T | 1 |
| Peleg, AY | 1 |
| Furiga, A | 1 |
| Lajoie, B | 1 |
| El Hage, S | 1 |
| Baziard, G | 1 |
| Roques, C | 1 |
| Gillard, CJ | 1 |
| Al-Dahir, S | 1 |
| Brakta, F | 1 |
| Azarkar, Z | 1 |
| Bidaki, MZ | 1 |
| Greenbarg, EH | 1 |
| Secrest, SA | 1 |
| Hansen, CR | 1 |
| Pressler, T | 1 |
| Høiby, N | 1 |
| Matsuo, K | 1 |
| Azuma, M | 1 |
| Kasai, M | 1 |
| Hanji, I | 1 |
| Kimura, I | 1 |
| Kosugi, T | 1 |
| Suga, N | 1 |
| Satoh, M | 1 |
| Dambrauskiene, A | 1 |
| Adukauskiene, D | 1 |
| Jeroch, J | 1 |
| Vitkauskiene, A | 1 |
| Elborn, JS | 1 |
| Hodson, M | 1 |
| Bertram, C | 1 |
| Migone, TS | 1 |
| Subramanian, GM | 1 |
| Zhong, J | 1 |
| Healey, LM | 1 |
| Corey, A | 1 |
| Devalaraja, M | 1 |
| Lo, L | 1 |
| Ullrich, S | 1 |
| Zimmerman, J | 1 |
| Chen, A | 1 |
| Lewis, M | 1 |
| Meister, G | 1 |
| Gillum, K | 1 |
| Sanford, D | 1 |
| Mott, J | 1 |
| Bolmer, SD | 1 |
| Oostdijk, EA | 1 |
| de Smet, AM | 1 |
| Blok, HE | 1 |
| Thieme Groen, ES | 1 |
| van Asselt, GJ | 1 |
| Benus, RF | 1 |
| Bernards, SA | 1 |
| Frénay, IH | 1 |
| Jansz, AR | 1 |
| de Jongh, BM | 2 |
| Kaan, JA | 1 |
| Leverstein-van Hall, MA | 1 |
| Mascini, EM | 1 |
| Pauw, W | 1 |
| Sturm, PD | 1 |
| Thijsen, SF | 1 |
| Kluytmans, JA | 1 |
| Bonten, MJ | 1 |
| Drago, L | 1 |
| Nicola, L | 1 |
| Mattina, R | 1 |
| De Vecchi, E | 1 |
| Stinner, DJ | 1 |
| Orr, JD | 1 |
| Hsu, JR | 1 |
| Glass, SK | 1 |
| Pearl, DL | 1 |
| McEwen, SA | 1 |
| Finley, R | 1 |
| Chono, S | 4 |
| Suzuki, H | 1 |
| Togami, K | 1 |
| Morimoto, K | 3 |
| Fagan, M | 1 |
| Skotheim, SB | 1 |
| Isbaniah, F | 1 |
| Wiyono, WH | 1 |
| Yunus, F | 1 |
| Setiawati, A | 1 |
| Totzke, U | 1 |
| Verbruggen, MA | 1 |
| Wood, J | 1 |
| Butler, CC | 1 |
| Hood, K | 1 |
| Kelly, MJ | 1 |
| Verheij, T | 1 |
| Little, P | 1 |
| Torres, A | 1 |
| Blasi, F | 1 |
| Schaberg, T | 1 |
| Goossens, H | 1 |
| Nuttall, J | 1 |
| Coenen, S | 1 |
| Growcott, EJ | 1 |
| Coulthard, A | 1 |
| Amison, R | 1 |
| Hardaker, EL | 1 |
| Saxena, V | 1 |
| Malt, L | 1 |
| Jones, P | 1 |
| Grevot, A | 1 |
| Poll, C | 1 |
| Osborne, C | 1 |
| Banner, KH | 1 |
| Nelson, M | 1 |
| Stagg, AJ | 1 |
| Stevens, DJ | 1 |
| Brown, MA | 1 |
| Pearce, PC | 1 |
| Simpson, AJ | 1 |
| Lever, MS | 1 |
| Tiengrim, S | 1 |
| Phiboonbanakit, D | 1 |
| Thunyaharn, S | 1 |
| Santiwatanakul, S | 1 |
| Susaengrat, W | 1 |
| Srisurat, N | 1 |
| Malithong, A | 1 |
| Srisangchan, P | 1 |
| Thamlikitkul, V | 1 |
| Serisier, DJ | 1 |
| Bogomolova, NS | 1 |
| Parshin, VD | 1 |
| Vishnevskaia, GA | 1 |
| Bol'shakov, LV | 1 |
| Kuznetsova, SM | 1 |
| Gollard, R | 1 |
| Rahman, S | 1 |
| Ratnasabapathy, R | 1 |
| Antonela Antoniu, S | 1 |
| Wei, Y | 1 |
| Wang, J | 1 |
| García-Rey, C | 2 |
| Martín-Sánchez, AM | 1 |
| Aguilar, L | 3 |
| Ruiz, J | 1 |
| Sánchez Navarro, MD | 1 |
| Coloma Milano, C | 1 |
| Zarzuelo Castañeda, A | 1 |
| Sayalero Marinero, ML | 1 |
| Sánchez-Navarro, A | 1 |
| Matsuzaki, K | 2 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 2 |
| Hasegawa, M | 2 |
| Kobayashi, I | 2 |
| Beovic, B | 1 |
| Matos, B | 1 |
| Bosnjak, R | 1 |
| Seme, K | 1 |
| Mueller-Premru, M | 1 |
| Hergouth-Krizan, V | 1 |
| Cizman, M | 1 |
| Magalhães, M | 1 |
| de Britto, MC | 1 |
| Vandamme, P | 1 |
| Sadowy, E | 1 |
| Izdebski, R | 1 |
| Skoczyńska, A | 1 |
| Gniadkowski, M | 1 |
| Hryniewicz, W | 1 |
| Fuller, JD | 1 |
| Low, DE | 1 |
| Rókusz, L | 1 |
| László, L | 1 |
| Peralta, S | 1 |
| Accursio, A | 1 |
| Filaci, G | 1 |
| Vitale, B | 1 |
| D'Aiello, G | 1 |
| Scarsi, C | 1 |
| Collura, D | 1 |
| Rini, GB | 1 |
| Brückner, O | 1 |
| Trautmann, M | 2 |
| Beuscart, C | 1 |
| Leroy, O | 1 |
| Chidiac, C | 1 |
| Houriez, S | 1 |
| Caillaux, M | 1 |
| Beaucaire, G | 1 |
| Mouton, Y | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Altraja, A | 1 |
| Naaber, P | 1 |
| Tamm, E | 1 |
| Meriste, S | 1 |
| Kullamaa, A | 1 |
| Leesik, H | 1 |
| Tanino, T | 2 |
| Seki, T | 2 |
| Omika, K | 1 |
| van Hees, BC | 1 |
| de Ruiter, E | 1 |
| Wiltink, EH | 1 |
| Tersmette, M | 1 |
| Hoogkamp-Korstanje, JA | 2 |
| Scaglione, F | 1 |
| Scamazzo, F | 1 |
| Arcidiacono, MM | 1 |
| Cogo, R | 1 |
| Monzani, GP | 1 |
| Fraschini, F | 1 |
| Le Huec, JC | 1 |
| Schaeverbeke, T | 1 |
| Chauveaux, D | 1 |
| Rivel, J | 1 |
| Dehais, J | 1 |
| Le Rebeller, A | 1 |
| Watanabe, A | 1 |
| Shoji, S | 1 |
| Nukiwa, T | 1 |
| Nishino, T | 3 |
| Tsunoda, A | 1 |
| Shoji, M | 1 |
| Hoshi, Y | 1 |
| Sato, S | 1 |
| Nagashima, M | 1 |
| Aonuma, S | 1 |
| Lorian, V | 2 |
| Pavletich, K | 1 |
| Donaldson, PM | 1 |
| Pallett, AP | 1 |
| Carroll, MP | 1 |
| Jones, RN | 1 |
| Hoban, DJ | 1 |
| Quartieri, F | 1 |
| Bolognesi, S | 1 |
| Sconosciuto, F | 1 |
| Wiseman, LR | 1 |
| Balfour, JA | 1 |
| Körner, RJ | 1 |
| Reeves, DS | 1 |
| MacGowan, AP | 1 |
| Louie, TJ | 1 |
| Tsang, KW | 1 |
| Rutman, A | 1 |
| Kanthakumar, K | 1 |
| Belcher, J | 1 |
| Lund, V | 1 |
| Roberts, DE | 1 |
| Read, RC | 1 |
| Cole, PJ | 1 |
| Wilson, R | 1 |
| Imrie, K | 1 |
| Gold, W | 1 |
| Salit, I | 1 |
| Keating, A | 1 |
| Malmborg, AS | 1 |
| Ahlén, S | 1 |
| Visser, MR | 1 |
| Beumer, H | 1 |
| Hoepelman, AI | 1 |
| Rozenberg-Arska, M | 1 |
| Verhoef, J | 1 |
| Sollich, V | 1 |
| Klöditz, E | 1 |
| Schuster, R | 1 |
| Handrick, W | 1 |
| Brömme, S | 1 |
| Rumler, W | 1 |
| Patsch, R | 1 |
| Kharari, H | 1 |
| Spencker, FB | 1 |
| Barriere, SL | 1 |
| Hindler, JA | 1 |
| Cunliffe, NA | 1 |
| Emmanuel, FX | 1 |
| Thomson, CJ | 1 |
| Lozano Ayllón, M | 1 |
| Gómez Martinez, M | 1 |
| Mosquera, MR | 1 |
| Laguna Martinez, JJ | 1 |
| Orta Martiartu, M | 1 |
| Fernández de Miguel, C | 1 |
| Goldstein, FW | 1 |
| Acar, JF | 1 |
| Marklein, G | 1 |
| Crokaert, F | 1 |
| Aoun, M | 1 |
| Duchateau, V | 1 |
| Grenier, P | 1 |
| Vandermies, A | 1 |
| Klastersky, J | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Wise, R | 2 |
| Andrews, JM | 2 |
| Eltahawy, AT | 1 |
| Felmingham, D | 2 |
| Robbins, MJ | 2 |
| Tesfaslasie, Y | 1 |
| Harding, I | 1 |
| Shrimpton, S | 1 |
| Grüneberg, RN | 2 |
| Weber, P | 1 |
| Alarcón, T | 1 |
| Domingo, D | 1 |
| Prieto, N | 1 |
| Sánchez, S | 1 |
| López-Brea, M | 1 |
| Cisterna, R | 1 |
| Fresnadillo, MJ | 1 |
| García-Rodríguez, JA | 1 |
| Gobernado, M | 1 |
| Martín, R | 1 |
| Perea, E | 1 |
| Picazo, J | 1 |
| Piddock, LJ | 1 |
| Johnson, M | 1 |
| Ricci, V | 1 |
| Hill, SL | 1 |
| Belousov, IuB | 1 |
| Komarova, VP | 1 |
| Efremenkova, OV | 1 |
| Blondeau, JM | 2 |
| Yaschuk, Y | 1 |
| Suter, M | 2 |
| Vaughan, D | 1 |
| Borsos, S | 1 |
| Highet, VS | 1 |
| Forrest, A | 1 |
| Ballow, CH | 1 |
| Schentag, JJ | 3 |
| Jaffé, A | 1 |
| Bush, A | 1 |
| Marre, R | 1 |
| Ohmichi, M | 1 |
| Hiraga, Y | 1 |
| Fuentes, F | 1 |
| Giménez, MJ | 1 |
| Marco, F | 2 |
| Alou, L | 1 |
| Prieto, J | 1 |
| Pea, F | 1 |
| Milaneschi, R | 1 |
| Baraldo, M | 1 |
| Lugatti, E | 1 |
| Talmassons, G | 1 |
| Furlanut, M | 1 |
| Yamaguchi, K | 1 |
| Miyazaki, S | 1 |
| Kashitani, F | 1 |
| Iwata, M | 1 |
| Kanda, M | 1 |
| Tsujio, Y | 1 |
| Okada, J | 1 |
| Tazawa, Y | 1 |
| Watanabe, N | 1 |
| Uehara, N | 1 |
| Igari, J | 1 |
| Oguri, T | 1 |
| Kaimori, M | 1 |
| Kawamura, C | 1 |
| Iinuma, Y | 1 |
| Nisawataira, T | 1 |
| Tashiro, H | 1 |
| Ueno, K | 1 |
| Ishigo, S | 1 |
| Yasujima, M | 1 |
| Kawahara, S | 1 |
| Itoh, C | 1 |
| Yoshida, T | 1 |
| Yamanaka, K | 1 |
| Toyoshima, S | 1 |
| Katoh, J | 1 |
| Kudoh, M | 1 |
| Matsushima, T | 1 |
| Niki, Y | 1 |
| Miyashita, N | 1 |
| Funato, T | 1 |
| Kaku, M | 1 |
| Sato, N | 1 |
| Saito, Y | 1 |
| Ishii, K | 1 |
| Kuwabara, M | 1 |
| Hongo, T | 1 |
| Negayama, K | 1 |
| Kamihira, S | 1 |
| Miyazaki, Y | 1 |
| Takii, M | 1 |
| Ishii, M | 1 |
| Nakagawa, K | 1 |
| Ono, J | 1 |
| Takada, T | 1 |
| Murakami, N | 1 |
| Taira, M | 1 |
| Tamaki, I | 1 |
| Matsudou, Y | 1 |
| Nakasone, I | 1 |
| Karcic, AA | 1 |
| Khan, FA | 3 |
| Postnikov, SS | 1 |
| Bouza, E | 1 |
| Fernández-Mazarrasa, C | 1 |
| Enserink, M | 1 |
| Lemonick, MD | 1 |
| Lopez, H | 1 |
| Vilches, V | 1 |
| Scarano, S | 1 |
| Stepanik, D | 1 |
| Smayevsky, J | 1 |
| Lemme, L | 1 |
| Cardeñosa, O | 1 |
| Ambler, J | 1 |
| Sucari, A | 1 |
| SoRelle, R | 1 |
| Carabias, ML | 1 |
| Cervera, LA | 1 |
| García-Navas, BL | 1 |
| entelles, ML | 1 |
| Mayer, TA | 1 |
| Bersoff-Matcha, S | 1 |
| Murphy, C | 1 |
| Earls, J | 1 |
| Harper, S | 1 |
| Pauze, D | 1 |
| Nguyen, M | 1 |
| Rosenthal, J | 1 |
| Cerva, D | 1 |
| Druckenbrod, G | 1 |
| Hanfling, D | 1 |
| Fatteh, N | 1 |
| Napoli, A | 1 |
| Nayyar, A | 1 |
| Berman, EL | 1 |
| Wirtschafter, A | 1 |
| Cherukuri, S | 1 |
| Benninger, MS | 1 |
| Lindsay, G | 1 |
| Scorer, HJ | 1 |
| Carnegie, CM | 1 |
| Bingen, E | 1 |
| Denamur, E | 2 |
| Picard, B | 1 |
| Goullet, P | 1 |
| Lambert-Zechovsky, N | 1 |
| Foucaud, P | 1 |
| Navarro, J | 1 |
| Elion, J | 1 |
| Dubois, J | 1 |
| Joly, JR | 1 |
| Kalager, T | 1 |
| Andersen, BM | 1 |
| Bergan, T | 1 |
| Brubakk, O | 1 |
| Bruun, JN | 1 |
| Døskeland, B | 1 |
| Hellum, KB | 1 |
| Hopen, G | 1 |
| von der Lippe, E | 1 |
| Rahm, V | 1 |
| Teramoto, S | 1 |
| Fukuchi, Y | 1 |
| Nagase, T | 1 |
| Orimo, H | 1 |
| Iakovlev, VP | 1 |
| Memoli, M | 1 |
| Cherubin, CE | 1 |
| Eng, RH | 1 |
| Smith, SM | 1 |
| Tan, EN | 1 |
| Chodosh, S | 1 |
| Davey, PG | 1 |
| Hardy, DJ | 3 |
| Kosmidis, J | 1 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kimura, K | 1 |
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kise, M | 1 |
| Shibata, K | 1 |
| Otsuki, M | 1 |
| Lee, BL | 1 |
| Padula, AM | 1 |
| Kimbrough, RC | 1 |
| Jones, SR | 1 |
| Chaisson, RE | 1 |
| Mills, J | 1 |
| Sande, MA | 1 |
| Gisby, J | 1 |
| Wightman, BJ | 1 |
| Beale, AS | 1 |
| Santini, C | 1 |
| Baiocchi, P | 1 |
| Venditti, M | 1 |
| Gelfusa, V | 1 |
| Tarasi, A | 1 |
| Brandimarte, C | 1 |
| Serra, P | 1 |
| Yoshida, M | 1 |
| Watanabe, K | 1 |
| Tamaru, N | 1 |
| Ishibashi, T | 1 |
| Takamoto, M | 1 |
| Yamada, H | 1 |
| Katoh, O | 1 |
| Yamaguchi, T | 1 |
| Ando, M | 1 |
| Matsumoto, M | 1 |
| Kikuchi, N | 1 |
| Kawashima, T | 1 |
| Yamagishi, F | 1 |
| Suzuki, K | 1 |
| Yasuda, J | 1 |
| Niijima, Y | 1 |
| Mizutani, F | 1 |
| Tabeta, H | 1 |
| Swanson, RN | 1 |
| Chu, DT | 1 |
| Shipkowitz, NL | 1 |
| Clement, JJ | 1 |
| Scarlini, GF | 1 |
| Germani, M | 1 |
| Martino, M | 1 |
| Perna, R | 1 |
| Poggi, F | 1 |
| Tognazzi, F | 1 |
| Doddi, M | 1 |
| Lauri, A | 1 |
| Placidi, C | 1 |
| Karimi, K | 1 |
| Lode, H | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 1 |
| Allon, M | 1 |
| Lopez, EJ | 1 |
| Min, KW | 1 |
| Orenstein, DM | 1 |
| Pattishall, EN | 1 |
| Nixon, PA | 1 |
| Ross, EA | 1 |
| Kaplan, RM | 1 |
| Aswapokee, N | 1 |
| Pruksachatvuthi, S | 1 |
| Aswapokee, P | 1 |
| Feld, MS | 1 |
| Carnegie, C | 1 |
| Macklin, J | 1 |
| Coles, S | 1 |
| Peloquin, CA | 2 |
| Cumbo, TJ | 2 |
| Nix, DE | 2 |
| Sands, MF | 2 |
| Brown, RB | 1 |
| Phillips, D | 1 |
| Barker, MJ | 1 |
| Pieczarka, R | 1 |
| Sands, M | 1 |
| Teres, D | 1 |
| Marcos Sánchez, F | 1 |
| Parrilla Herranz, P | 1 |
| Celdran Gil, J | 1 |
| Durán Peréz-Navarro, A | 1 |
| Hirata, CA | 1 |
| Guay, DR | 4 |
| Awni, WM | 3 |
| Stein, DJ | 1 |
| Peterson, PK | 4 |
| Waldvogel, FA | 1 |
| Haverkorn, MJ | 3 |
| Pedersen, SS | 1 |
| Basir, R | 1 |
| Haddow, A | 1 |
| Greene, S | 1 |
| Heinz, G | 1 |
| Wantuck, D | 1 |
| Menon, L | 1 |
| Ernst, JA | 1 |
| Sy, ER | 1 |
| Flores, D | 1 |
| Pacia, A | 1 |
| Trenholme, GM | 1 |
| Schmitt, BA | 1 |
| Spear, J | 1 |
| Gvazdinskas, LC | 1 |
| Levin, S | 1 |
| Modai, J | 1 |
| Baskerville, AJ | 1 |
| Sanghrajka, MD | 1 |
| Ridgway, GL | 1 |
| Brutel de la Rivière, T | 1 |
| Daniëls-Bosman, MS | 1 |
| ten Velde, GP | 1 |
| Smith, MJ | 1 |
| Hodson, ME | 2 |
| Batten, JC | 1 |
| Neu, HC | 3 |
| Moore, B | 1 |
| Safani, M | 1 |
| Keesey, J | 1 |
| Vellend, H | 1 |
| Ramirez, CA | 1 |
| Bran, JL | 1 |
| Mejia, CR | 1 |
| Garcia, JF | 1 |
| Kurz, CC | 1 |
| Marget, W | 1 |
| Harms, K | 1 |
| Bertele, RM | 1 |
| Newsom, SW | 1 |
| Bergogne-Bérézin, E | 1 |
| Berthelot, G | 1 |
| Even, P | 1 |
| Stern, M | 1 |
| Reynaud, P | 1 |
| Ball, AP | 1 |
| Stein, D | 2 |
| Logan, G | 1 |
| Obaid, S | 3 |
| Gruninger, R | 1 |
| Davies, S | 1 |
| Breitenbucher, R | 3 |
| Nakatomi, M | 1 |
| Suermondt, G | 1 |
| Laurans, G | 1 |
| Orfila, J | 1 |
| Obana, Y | 1 |
| Sforza, E | 1 |
| De Gennaro, M | 1 |
| Ruggieri, A | 1 |
| Ninno, D | 1 |
| Pastore, G | 1 |
| Esposito, S | 3 |
| Galante, D | 3 |
| Barba, D | 2 |
| Bianchi, W | 2 |
| Gagliardi, R | 2 |
| Giusti, R | 1 |
| Ohno, I | 1 |
| Ida, S | 1 |
| Arcieri, G | 2 |
| Griffith, E | 2 |
| Gruenwaldt, G | 2 |
| Heyd, A | 2 |
| O'Brien, B | 2 |
| Screen, P | 1 |
| Becker, N | 2 |
| August, R | 2 |
| Matzke, GR | 2 |
| Davies, BI | 1 |
| Maesen, FP | 1 |
| Stutman, HR | 1 |
| Shalit, I | 1 |
| Marks, MI | 1 |
| Greenwood, R | 1 |
| Chartrand, SA | 1 |
| Hilman, BC | 1 |
| Wollschlager, CM | 1 |
| Raoof, S | 2 |
| Guarneri, JJ | 1 |
| LaBombardi, V | 1 |
| Afzal, Q | 1 |
| Kobayashi, H | 1 |
| Fass, RJ | 1 |
| Vari, AJ | 1 |
| Vance, JW | 1 |
| Fracasso, JE | 1 |
| Raeburn, JA | 1 |
| Govan, JR | 1 |
| McCrae, WM | 1 |
| Greening, AP | 1 |
| Collier, PS | 1 |
| Goodchild, MC | 1 |
| Giusti, G | 1 |
| Gleadhill, IC | 1 |
| Ferguson, WP | 1 |
| Lowry, RC | 1 |
| Wollschlager, C | 1 |
| Khan, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT01515007] | Phase 3 | 278 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT02104245] | Phase 3 | 304 participants (Actual) | Interventional | 2014-05-28 | Completed | ||
| A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects[NCT00639678] | Phase 3 | 322 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients[NCT01551186] | Phase 4 | 103 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [NCT02729116] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients[NCT00050310] | 200 participants (Anticipated) | Observational | 2002-10-31 | Recruiting | |||
| Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study[NCT00137956] | Phase 3 | 270 participants | Interventional | 2004-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants who developed an anti-raxibacumab antibody response during the study were assessed. .Immunogenicity testing was performed to determine if raxibacumab induced an anti-raxibacumab immune response. Testing comprised of 2 assays (screening and confirmatory). The screening assay (direct binding) was an electrochemiluminescence (ECL)-based bridging assay. A rabbit polyclonal antibody was used as a positive control. Samples above the assay cut point were considered positive. Samples identified as positive in the screening assay were confirmed positive in a confirmatory assay. Samples must have demonstrated a significant percent drop in the confirmatory inhibition of binding assay to be considered positive. The inhibition of binding confirmatory assay was performed identically to the direct binding screening assay with the exception that the samples were tested in parallel with excess unlabeled raxibacumab. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Clinical thyroid parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. Blood samples for serum raxibacumab concentration measurement were collected from participants who received a single-dose prior to administration of the raxibacumab and diphenhydramine doses on Day 0, at 30 minutes and 2 to 6 hours after completion of the raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Day 0, at 30 minutes and 2 to 6 hours after completion of raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Predose | 30 minutes post-dose | 2-6 hours post-dose | Day 14 | Day 28 | Day 56 | |
| Raxibacumab - Single-Dose | 0.048 | 928.447 | 881.586 | 311.669 | 199.043 | 89.021 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. For the participants that received two doses, blood samples for serum raxibacumab concentration measurement were collected from participants prior to administration of the raxibacumab and diphenhydramine doses on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 1 - Predose | Dose 1 - 30 minutes post-dose | Dose 1 - 2-6 hours post-dose | Dose 2 - Predose | Dose 2 - 30 minutes post-dose | Dose 2 - 2-6 hours post-dose | Dose 2 - Day 14 | Dose 2 - Day 28 | Dose 2 - Day 42 | Dose 2 - Day 56 | |
| Raxibacumab - Double-Dose | 0 | 1012.564 | 973.910 | 314.374 | 1246.223 | 1211.572 | 543.767 | 334.431 | 213.463 | 137.878 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes worsening (eg, increase in frequency or severity) of pre-existing conditions. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Any AE | Any SAE | |
| Placebo - Double-Dose | 6 | 1 |
| Placebo - Single-Dose | 32 | 0 |
| Raxibacumab - Double-Dose | 10 | 1 |
| Raxibacumab - Single-Dose | 103 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in electrolyte toxicities were assessed. Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, any >=2-grade worsening | Hyponatremia, any >=2-grade worsening | Hyperkalemia, any >=2-grade worsening | Hypokalemia, any >=2-grade worsening | Hypomagnesemia, any >=2-grade worsening | HrC/adjusted for albumin, any >=2-grade worsening | HoC/adjusted for albumin, any >=2-grade worsening | Hypercalcemia/unadjusted, any >=2-grade worsening | Hypocalcemia/unadjusted, any >=2-grade worsening | Hypophosphatemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 5 |
The number of participants with at least a 2-grade worsening from Baseline in hematological toxicities were assessed. Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Leukocytosis, any >=2-grade worsening | Leukopenia, any >=2-grade worsening | Neutropenia, any >=2-grade worsening | Lymphopenia, any >=2-grade worsening | Hemoglobin, any >=2-grade worsening | Platelet, any >=2-grade worsening | Prothrombin Time, any >=2-grade worsening | Activated PTT, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 1 | 2 | 1 | 0 | 0 | 2 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in liver toxicities were assessed. Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AST, any >=2-grade worsening | ALT, any >=2-grade worsening | GGT, any >=2-grade worsening | ALP, any >=2-grade worsening | Hyperbilirubinemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 1 | 0 | 0 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in other chemistry toxicities were assessed. Other clinical chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Creatinine, any >=2-grade worsening | BUN, any >=2-grade worsening | Hypoalbuminemia, any >=2-grade worsening | Hyperuricemia, any >=2-grade worsening | Hyperglycemia, any >=2-grade worsening | Hypoglycemia, any >=2-grade worsening | Amylase, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
Urinalysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Proteinuria, any >=2-grade worsening | Hematuria, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 |
| Placebo - Single-Dose | 3 | 4 |
| Raxibacumab - Double-Dose | 0 | 2 |
| Raxibacumab - Single-Dose | 8 | 12 |
Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hypomagnesemia, Grade 1 | Hypomagnesemia, Grade 2 | Hypomagnesemia, Grade 3 | Hypomagnesemia, Grade 4 | Hypercalcemia (HrC)/ adjusted for albumin, Grade 1 | HrC/ adjusted for albumin, Grade 2 | HrC/ adjusted for albumin, Grade 3 | HrC/ adjusted for albumin, Grade 4 | Hypocalcemia (HoC)/ adjusted for albumin, Grade 1 | HoC adjusted for albumin, Grade 2 | HoC/ adjusted for albumin, Grade 3 | HoC/ adjusted for albumin, Grade 4 | Hypercalcemia/ unadjusted, Grade 1 | Hypercalcemia/ unadjusted, Grade 2 | Hypercalcemia/ unadjusted, Grade 3 | Hypercalcemia/ unadjusted, Grade 4 | Hypocalcemia/ unadjusted, Grade 1 | Hypocalcemia/ unadjusted, Grade 2 | Hypocalcemia/ unadjusted, Grade 3 | Hypocalcemia/ unadjusted, Grade 4 | Hypophosphatemia, Grade 1 | Hypophosphatemia, Grade 2 | Hypophosphatemia, Grade 3 | Hypophosphatemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 5 | 0 | 0 |
Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukocytosis, Grade 1 | Leukocytosis, Grade 2 | Leukocytosis, Grade 3 | Leukocytosis, Grade 4 | Leukopenia, Grade 1 | Leukopenia, Grade 2 | Leukopenia, Grade 3 | Leukopenia, Grade 4 | Neutropenia, Grade 1 | Neutropenia, Grade 2 | Neutropenia, Grade 3 | Neutropenia, Grade 4 | Lymphopenia, Grade 1 | Lymphopenia, Grade 2 | Lymphopenia, Grade 3 | Lymphopenia, Grade 4 | Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Platelet, Grade 1 | Platelet, Grade 2 | Platelet, Grade 3 | Platelet, Grade 4 | Prothrombin Time, Grade 1 | Prothrombin Time, Grade 2 | Prothrombin Time, Grade 3 | Prothrombin Time, Grade 4 | Activated PartialThromboplastinTime(PTT) , Grade 1 | Activated PTT, Grade 2 | Activated PTT, Grade 3 | Activated PTT, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 4 | 1 | 1 | 0 | 9 | 1 | 0 | 0 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 2 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 15 | 2 | 1 | 0 | 25 | 6 | 0 | 0 | 8 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 10 | 0 | 0 | 0 |
Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate amino transferase (AST), Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Alanine amino transferase(ALT), Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Gamma-glutamyl-transferase (GGT), Grade 1 | GGT, Grade 2 | GGT, Grade 3 | GGT, Grade 4 | Alkaline Phosphatase(ALP), Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | Hyperbilirubinemia, Grade 1 | Hyperbilirubinemia, Grade 2 | Hyperbilirubinemia, Grade 3 | Hyperbilirubinemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 7 | 0 | 0 | 0 | 6 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
Other chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Blood Urea Nitrogen (BUN), Grade 1 | BUN, Grade 2 | BUN, Grade 3 | BUN, Grade 4 | Hypoalbuminemia, Grade 1 | Hypoalbuminemia, Grade 2 | Hypoalbuminemia, Grade 3 | Hypoalbuminemia, Grade 4 | Hyperuricemia, Grade 1 | Hyperuricemia, Grade 2 | Hyperuricemia, Grade 3 | Hyperuricemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Amylase, Grade 1 | Amylase, Grade 2 | Amylase, Grade 3 | Amylase, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 15 | 1 | 0 | 0 | 5 | 2 | 0 | 0 | 5 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 2 | 1 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 8 | 1 | 0 | 0 | 36 | 1 | 0 | 0 | 11 | 2 | 0 | 0 | 25 | 5 | 1 | 0 |
Urinaysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Proteinuria, Grade 1 | Proteinuria, Grade 2 | Proteinuria, Grade 3 | Proteinuria, Grade 4 | Hematuria, Grade 1 | Hematuria, Grade 2 | Hematuria, Grade 3 | Hematuria, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 9 | 3 | 0 | 0 | 9 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 3 | 0 | 0 | 0 | 3 | 2 | 0 | 0 |
| Raxibacumab - Single-Dose | 31 | 9 | 0 | 0 | 17 | 15 | 0 | 0 |
Colonization of the gastrointestinal tract with C. difficile, vancomycin-resistant enterococci, multidrug-resistant Acinetobacter baumannii, and multidrug- resistant Pseudomonas. Colonization occurs when the subject acquires the above organism while in the study. (NCT01551186)
Timeframe: Participants will be followed while Intubated, an expected average of 7 days. The outcome will be measured 3 days after enrollment and at the end of intubation, average time 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Probiotic | 8 |
| Standard of Care | 8 |
13 reviews available for ciprofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Ciprofloxa | 2015 |
Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Injections, Intravenous; Male; Me | 2009 |
Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical | 2012 |
Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Clinical Trials a | 2012 |
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; F | 2005 |
[Development of drug delivery systems for targeting to macrophages].
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Atherosclerosis; Ciprofloxacin; Dexamethas | 2007 |
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.
Topics: Bacterial Infections; Ciprofloxacin; Drug Interactions; Humans; Premedication; Respiratory Tract Inf | 1994 |
[A review of clinical studies on the efficacy and tolerance of intravenous ciprofloxacin].
Topics: Ciprofloxacin; Clinical Trials as Topic; Drug Tolerance; Humans; Injections, Intravenous; Respirator | 1992 |
Acute renal failure due to ciprofloxacin.
Topics: Acute Kidney Injury; Adult; Aged; Biopsy; Ciprofloxacin; Erythema Multiforme; Female; Humans; Kidney | 1990 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
Overview of clinical experience with ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enteritis; Enterob | 1986 |
Ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Respiratory Tract Infections | 1988 |
[Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance | 1987 |
43 trials available for ciprofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.
Topics: Acinetobacter baumannii; Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Ciprofloxaci | 2019 |
Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cip | 2015 |
Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cys | 2015 |
Raxibacumab for the treatment of inhalational anthrax.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anthrax; Anti-Infective Agents; Antibodies, Bac | 2009 |
Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ascorbic Acid; Ciprofloxacin; | 2011 |
Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
Topics: Adult; Bacterial Infections; Bronchi; Bronchoalveolar Lavage Fluid; Chronic Disease; Ciprofloxacin; | 1995 |
[Studies on respiratory infections in primary care clinic (V). The pattern of distribution on bacteria, Mycoplasma pneumoniae and virus isolated from patients with respiratory infections, who were seen in six private clinics, and clinical efficacy of cipr
Topics: Ciprofloxacin; Female; Humans; Male; Mycoplasma pneumoniae; Orthomyxoviridae; Respiratory Tract Infe | 1994 |
[The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract].
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Female; Humans; | 1994 |
[Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study].
Topics: Adolescent; Bacterial Infections; Child; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, | 1993 |
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Double-Blind Method; Female; Fle | 1996 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
[Selection of antibacterial therapy for treatment of infections in elderly patients].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Cefaclor; Cephalosporins | 1998 |
[The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association].
Topics: Adult; Aged; Amikacin; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Enterobacter | 1997 |
Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomized, double-blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Ciprofloxacin; Double-B | 1992 |
Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety.
Topics: Adult; Aged; Bacteremia; Cefuroxime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; | 1992 |
Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study.
Topics: Ambulatory Care; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones | 1991 |
Efficacy of temafloxacin versus ciprofloxacin or amoxicillin for lower respiratory tract infections in smokers and the elderly.
Topics: Age Factors; Aged; Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; F | 1991 |
A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections.
Topics: Adolescent; Adult; Anti-Infective Agents; Bronchitis; Ciprofloxacin; Double-Blind Method; Female; Fl | 1991 |
[Clinical studies on ciprofloxacin in chronic respiratory tract infection].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1991 |
[Clinical evaluation of ciprofloxacin in pulmonary infections in the patients with chronic respiratory diseases].
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pneumonia; Respirato | 1991 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; Ciproflox | 1990 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Ciprofloxacin in severe infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pse | 1990 |
Comparison of oral erythromycin ethylsuccinate and ciprofloxacin in the treatment of acute respiratory tract infections.
Topics: Adolescent; Adult; Aged; Ciprofloxacin; Erythromycin Ethylsuccinate; Female; Humans; Male; Middle Ag | 1990 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; Ciprofloxac | 1989 |
Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections.
Topics: Administration, Oral; Aged; Ceftazidime; Ciprofloxacin; Female; Humans; Infusions, Intravenous; Male | 1989 |
Sequential intravenous/oral ciprofloxacin compared with intravenous ceftazidime in the treatment of serious lower respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Ceftazidime; Ciprofloxacin; Clinical Trials as Topic; Female; Hum | 1989 |
Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Ceftazidime; Ciprofloxacin; Female; Humans; Infusions, Intravenou | 1989 |
Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ciprofloxacin; Female; H | 1989 |
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To | 1986 |
Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Cefamandole; Ciprofloxacin; Clinical Tria | 1988 |
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Liver Diseases | 1988 |
Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Ciprofloxacin; Clinical Trials as Topic; Dru | 1987 |
Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
Topics: Adult; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetics; Male; Res | 1987 |
Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1987 |
Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Clinical Trials as Topic; Diges | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Candidiasis, Oral; Ciprofloxacin; Clinical | 1987 |
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Cross Infect | 1987 |
Ciprofloxacin: an update on clinical experience.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Digestive System; Drug Resistance, Mi | 1987 |
Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin.
Topics: Aged; Aged, 80 and over; Amoxicillin; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Ran | 1986 |
167 other studies available for ciprofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Peptide deformylase inhibitors with activity against respiratory tract pathogens.
Topics: Amidohydrolases; Anti-Infective Agents; Enzyme Inhibitors; Haemophilus influenzae; Microbial Sensiti | 2004 |
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Hu | 2007 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; H | 2009 |
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
Topics: Ampicillin; Anti-Bacterial Agents; Cefotaxime; Erythromycin; Haemophilus influenzae; Lincosamides; M | 2010 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; M | 2013 |
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Drug Discovery; Gram-Negative Bacteria; Half-Life; | 2017 |
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacteria | 2018 |
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
Topics: Animals; Anti-Bacterial Agents; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbia | 2018 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensiti | 2022 |
Study of bacterial respiratory infections and antimicrobial susceptibility profile among antibiotics naive outpatients visiting Meru teaching and referral hospital, Meru County, Kenya in 2018.
Topics: Agar; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Humans; Kenya; Outpatients; Pip | 2023 |
Respiratory tract infection after oral and maxillofacial surgery under general anesthesia and related factors.
Topics: Anesthesia, General; Ciprofloxacin; Humans; Intubation, Intratracheal; Middle Aged; Respiratory Trac | 2023 |
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bacteriophages; Chemistry, Pharmaceutic | 2019 |
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?
Topics: Agar; Alginates; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Lung; Pseudo | 2019 |
Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
Topics: A549 Cells; Administration, Inhalation; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Combina | 2020 |
Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Gu | 2020 |
In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Biofilms; Chemistry, Pharmaceutical; Cip | 2020 |
Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; | 2021 |
Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Bacteriophages; Ciprofloxacin; Dry Powder Inhalers; Humans; Pa | 2020 |
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Topics: Animals; Cell Line; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Horses; Humans; Lactic Acid; Mucu | 2017 |
Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chronic Disease; Cipr | 2018 |
In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
Topics: Academic Medical Centers; Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; | 2017 |
Antibacterial activity of traditional spices against lower respiratory tract pathogens: combinatorial effects of Trachyspermum ammi essential oil with conventional antibiotics.
Topics: Ammi; Anti-Bacterial Agents; Carum; Ciprofloxacin; Cyclohexane Monoterpenes; Cymenes; Drug Resistanc | 2018 |
Ciprofloxacin-associated choreoathetosis in a haemodialysis patient.
Topics: Aged; Ciprofloxacin; Diagnosis, Differential; Dyskinesias; Humans; Male; Muscle Spasticity; Renal Di | 2013 |
Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters; Ciprofloxacin; Disease Models, Animal | 2013 |
Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Topics: Aerosols; Anti-Bacterial Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cipr | 2014 |
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, B | 2014 |
Chryseobacterium gleum - a novel bacterium species detected in neonatal respiratory tract infections.
Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Female; Flavobacteriaceae Infections; Humans; Infa | 2014 |
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Ciproflo | 2015 |
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Bacillus ant | 2015 |
[Population pharmacokinetics of ciprofloxacin in Chinese elderly patients with lower respiratory tract infection].
Topics: Aged; Anti-Bacterial Agents; Asian People; Ciprofloxacin; Humans; Infusions, Intravenous; Pseudomona | 2015 |
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Topics: Amides; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colistin; Cystic Fibrosi | 2015 |
Observations of resistance through minimum inhibitory concentrations trends for respiratory specimens of commonly isolated organisms.
Topics: Acinetobacter; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Imipenem; I | 2016 |
A case report of inhalation anthrax acquired naturally.
Topics: Aged; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Clindamycin; Fatal | 2016 |
What Is Your Diagnosis? Fungal pneumonia and aspergillosis.
Topics: Air Sacs; Animals; Anti-Infective Agents; Aspergillosis; Bird Diseases; Ciprofloxacin; Diagnosis, Di | 2016 |
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Child; C | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; | 2009 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia | 2009 |
Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftazidime; Ciprofloxacin; Cross Infection; Drug Res | 2010 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Ana | 2010 |
Fluoroquinolone-associated bilateral patellar tendon rupture: a case report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Follow-Up Studies; Humans; Male; Musc | 2010 |
A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
Topics: Anti-Bacterial Agents; Canada; Ciprofloxacin; Drug Utilization; Fluoroquinolones; Humans; Influenza, | 2010 |
Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections.
Topics: Aerosols; Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Delivery Systems; Ep | 2011 |
[Use of fluoroquinolones in nursing homes].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinar | 2010 |
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines.
Topics: Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Cough; Drug | 2011 |
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
Topics: Acute Disease; Agar; Animals; Anti-Infective Agents; Bacterial Load; Bronchoalveolar Lavage Fluid; C | 2011 |
Post-exposure therapy of inhalational anthrax in the common marmoset.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Callithrix; Ciprofloxacin; Disease Mode | 2011 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxaci | 2012 |
[Microbiological monitoring in therapy of patients with iatrogenic esophageotracheal fistula].
Topics: Acetamides; Anti-Bacterial Agents; Candida; Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance | 2012 |
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Ciprofloxac | 2013 |
First detection of VIM-4 metallo-β-lactamase-producing Citrobacter freundii in China.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Cefotaxime; China; Ciprofloxacin; Citrobacter freundii | 2013 |
Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.
Topics: Anti-Infective Agents; Ciprofloxacin; Data Collection; Drug Resistance, Microbial; Humans; Pneumococ | 2002 |
Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; | 2002 |
Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate.
Topics: Ambulatory Care; Ciprofloxacin; Contraindications; Fluoroquinolones; Humans; Ofloxacin; Otitis; Resp | 2003 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Female; Humans; Intracranial Aneurysm; Male; | 2003 |
Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child.
Topics: Amikacin; Anti-Infective Agents; Burkholderia; Burkholderia cepacia complex; Burkholderia Infections | 2002 |
High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field | 2005 |
Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Fema | 2005 |
Ciprofloxacin in the treatment of infections at different sites.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Escherichia coli Infections; Female; Hum | 1989 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
Treatment of bronchopulmonary infections by ciprofloxacin in an intensive care unit. Correlation between serum and bronchial concentrations and bacteriological results.
Topics: Anti-Bacterial Agents; Bronchopneumonia; Ciprofloxacin; Humans; Intensive Care Units; Pneumonia, Bac | 1989 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cefuroxime; Child; C | 2006 |
Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections.
Topics: Administration, Inhalation; Administration, Oral; Animals; Anti-Infective Agents; Area Under Curve; | 2007 |
[Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella p | 2007 |
Optimizing use of ciprofloxacin: a prospective intervention study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Prescriptions; Drug Resis | 2008 |
Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Liposomes; Lung; Macrophages, Alveolar; Ma | 2008 |
Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Dose-Response Relationship, Dr | 1984 |
Epicondylitis after treatment with fluoroquinolone antibiotics.
Topics: 4-Quinolones; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Male; Middle Aged; Orc | 1995 |
Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 1994 |
Ciprofloxacin in general practice.
Topics: Bronchitis; Ciprofloxacin; Family Practice; Humans; Respiratory Tract Infections | 1994 |
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Topics: Bacteria; Bacterial Infections; Canada; Ciprofloxacin; Enterobacteriaceae; Female; Genitalia; Humans | 1994 |
Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Community-Acquired Infections; Female; Humans; Mal | 1994 |
Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.
Topics: Administration, Oral; Ciprofloxacin; Diarrhea; Gram-Negative Bacterial Infections; Humans; Respirato | 1994 |
Haemophilus influenzae infection of human respiratory mucosa in low concentrations of antibiotics.
Topics: Adenoids; Amoxicillin; Anti-Bacterial Agents; Cephalosporins; Child, Preschool; Ciprofloxacin; Dose- | 1993 |
Ciprofloxacin-induced neutropenia and erythema multiforme.
Topics: Aged; Ciprofloxacin; Erythema Multiforme; Female; Humans; Neutropenia; Respiratory Tract Infections | 1993 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria | 1993 |
Changes in adherence of respiratory pathogens to HEp-2 cells induced by subinhibitory concentrations of sparfloxacin, ciprofloxacin, and trimethoprim.
Topics: Anti-Infective Agents; Bacteria; Bacterial Adhesion; Carcinoma; Ciprofloxacin; Fluoroquinolones; Hum | 1993 |
Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus Infections; Haemophil | 1993 |
Intravenous ciprofloxacin: a position statement by the Society of Infectious Diseases Pharmacists.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Gram-Positive Bacterial Infections; Humans; Injections, I | 1993 |
Lower respiratory tract infection due to ciprofloxacin resistant Moraxella catarrhalis.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Moraxella catarrhalis; Nei | 1995 |
Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin.
Topics: Ciprofloxacin; Cross Reactions; Drug Eruptions; Exanthema; Female; Humans; Middle Aged; Norfloxacin; | 1995 |
Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Ciprofloxacin; Community-Acquired Infections; Drug Re | 1996 |
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; | 1996 |
[Management of infection in respiratory tract diseases].
Topics: Amoxicillin; Bacterial Infections; Bronchitis; Bronchopneumonia; Child; Ciprofloxacin; Drug Costs; H | 1995 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1997 |
The activity of grepafloxacin against respiratory pathogens in the UK.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; England; Flu | 1997 |
Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blood; Carbapenems; Cephalosporins; Ciproflo | 1997 |
Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Ampicillin Resistance; Anti-Bacterial Age | 1998 |
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Le | 1998 |
[Bacteriology in community-acquired respiratory pathology].
Topics: Acute Disease; Ambulatory Care; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprof | 1998 |
[In vitro activity of trovafloxacin in 238 respiratory pathogens].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Tec | 1998 |
[Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae].
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti- | 1998 |
Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus; Humans; Microbial Sen | 1998 |
In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefoperazone; Ceftazidime; Ciprofloxacin; Clavulanic Acids; En | 1999 |
Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Haemophilus influenzae; | 1999 |
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
Topics: Aged; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cephalosporins; Ciprofloxacin; Dose-Resp | 1999 |
If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin.
Topics: Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Dermatitis, Photoallergic; Female; Hum | 1999 |
[Community-acquired respiratory tract infections. Current data on the efficacy of various classes of antibiotics and antibiotic resistance of the main prevalent bacteria species].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Communi | 1999 |
The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchiolitis; Ciprofloxacin; Female; Humans; In | 1999 |
In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Hu | 2000 |
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Drug Mo | 2000 |
[Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Ba | 2000 |
Ciprofloxacin vs. the pneumococcus.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Pneumococcal Infections; Respiratory Tract Infections; | 2000 |
[Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
Topics: Adolescent; Anti-Infective Agents; Arthritis; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosi | 2001 |
Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Haemophilus Infections; Haemophilus influenza | 2001 |
Bioterrorism. Researchers question obsession with Cipro.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antigens, Bacterial; Bacillus anthracis; Bact | 2001 |
Anthrax. Deadly delivery.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Humans; Respiratory Tract Infections; S | 2001 |
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.
Topics: Adult; Aged; Anthrax; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Female | 2001 |
Post-exposure anthrax prophylaxis.
Topics: Abdominal Pain; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Anti-Infective Agents; Ba | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoro | 2001 |
Attempts to stem Anthrax fears stumble.
Topics: Adrenal Cortex Hormones; Anthrax; Bacillus anthracis; Bioterrorism; Centers for Disease Control and | 2001 |
Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Chi | 2001 |
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Community-Acquired Infections; Dr | 2001 |
Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bioterrorism; Blood; Ciprofloxacin; Clindamycin; | 2001 |
Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.
Topics: Adult; Amoxicillin; Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bioterrorism; Breast Fee | 2001 |
From the Centers for Disease Control and Prevention. Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.
Topics: Adult; Aged; Anthrax; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Female | 2001 |
From the Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Chi | 2001 |
From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
From the Centers for Disease Control and Prevention. Recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.
Topics: Adult; Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bioterrorism; Breast Feeding; Child; | 2001 |
From the Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Anthrax: ENT manifestations and current concepts.
Topics: Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Ciprofl | 2002 |
Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.
Topics: Azlocillin; Bacterial Typing Techniques; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistanc | 1992 |
In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Erythromycin; Humans; In Vitro Technique | 1992 |
[Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases].
Topics: Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Drug Evaluation; Humans; Respiratory Tract | 1992 |
[Symposium "Ciflozin (ciprofloxacin)--a broad-spectrum antibacterial drug"].
Topics: Bacterial Infections; Ciprofloxacin; Drug Evaluation; Germany, West; Humans; Moscow; Respiratory Tra | 1992 |
A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens.
Topics: Administration, Oral; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Ciprof | 1992 |
Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Test | 1991 |
In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Topics: Anti-Infective Agents; Campylobacter; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Nega | 1991 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluati | 1991 |
Infectious complications with respiratory pathogens despite ciprofloxacin therapy.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; Male; | 1991 |
Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefaclor; Ciprofloxacin; Cla | 1991 |
Intravenous ciprofloxacin for the treatment of severe infections.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Connective Tissue Diseases; Female; Humans; Inject | 1991 |
Activity of temafloxacin against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Dose-Response | 1991 |
[Ciprofloxacin: a new fluoroquinolone for the treatment of respiratory tract infections].
Topics: Acute Disease; Adult; Aged; Ciprofloxacin; Female; Humans; Male; Middle Aged; Respiratory Tract Infe | 1991 |
[Ciprofloxacin in the treatment of respiratory infections].
Topics: Adolescent; Adult; Aged; Ciprofloxacin; Drug Tolerance; Female; Humans; Male; Middle Aged; Respirato | 1990 |
Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis.
Topics: Attitude to Health; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas Infections; Quality of Life; | 1990 |
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Topics: Aged; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Drug Resistance, Microbi | 1989 |
Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B.
Topics: Administration, Inhalation; Bacterial Infections; Ciprofloxacin; Cross Infection; Disease Outbreaks; | 1989 |
[The efficacy of oral ciprofloxacin in the treatment of Proteus mirabilis infections of the lower respiratory tract].
Topics: Administration, Oral; Ciprofloxacin; Drug Evaluation; Humans; Proteus Infections; Proteus mirabilis; | 1989 |
Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ciprofloxacin; Female; Half-Life; Humans; Injections, | 1989 |
Clinical role of the quinolones today and in the future.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Protocols; Forecasting; Humans; | 1989 |
Prophylaxis of respiratory tract infection in patients on artificial respiration.
Topics: Amphotericin B; Bronchitis; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Feces; Female | 1989 |
Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Respiratory Tra | 1989 |
Two different dosages of ciprofloxacin in patients with respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Humans; Lung Diseases, Obstructive; Male; Mid | 1989 |
Ciprofloxacin in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pseud | 1986 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
Possible exacerbation of myasthenia gravis by ciprofloxacin.
Topics: Adult; Ciprofloxacin; Female; Humans; Myasthenia Gravis; Respiratory Tract Infections | 1988 |
Role of fluoroquinolones in lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bronchi; Bronchitis; Ciprofloxacin; Cystic Fibrosis; Gram-Negative B | 1989 |
Open, prospective study of the clinical efficacy of ciprofloxacin.
Topics: Adolescent; Adult; Aged; Arthritis; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Di | 1985 |
The clinical use of quinolones.
Topics: Ciprofloxacin; Escherichia coli; Feces; Female; Genital Diseases, Female; Genital Diseases, Male; Hu | 1986 |
Penetration of ciprofloxacin into bronchial secretions.
Topics: Aged; Anti-Bacterial Agents; Bronchi; Bronchial Diseases; Bronchoscopy; Ciprofloxacin; Humans; Kinet | 1986 |
[Clinical study on development of resistance of respiratory bacterial pathogens to ofloxacin and ciprofloxacin].
Topics: Adult; Bacteria; Child; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; Male; Microbial S | 1987 |
[In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; In Vitro Techniques; Microbial S | 1988 |
Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Humans; Middle Aged; Pse | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |
[Effectiveness of ciprofloxacin in bacterial infections of the respiratory and gastrointestinal tract].
Topics: Adult; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Diseases; Humans; Male; Respira | 1988 |
A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Res | 1988 |
Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; | 1988 |
Clinical efficacy of the new quinolones in lower respiratory infections.
Topics: Aged; Anti-Infective Agents; Bacteria; Ciprofloxacin; Enoxacin; Humans; Microbial Sensitivity Tests; | 1987 |
Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ciprofloxacin; Female; Half-Life; Humans; Kinetics; M | 1987 |
Ciprofloxacin: an overview and prospective appraisal.
Topics: Administration, Oral; Animals; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Disease Models, | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; C-Reactive Protein; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas In | 1987 |
Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease.
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Liver Diseases; Male; Middle Aged; Resp | 1986 |
Treatment of respiratory tract infections with ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; | 1986 |